Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Pharma
Daiichi, Eisai, Granules—Fierce Pharma Asia
Merck and Daiichi's HER3 ADC delivered a positive phase 3 result. An FDA document details shortfalls at a Granules plant in India. Plus more.
Angus Liu
Sep 20, 2024 10:16am
Akeso-Summit, BIOSECURE, Candid and more—Fierce Pharma Asia
Sep 13, 2024 8:53am
Gilead unfolds Trodelvy triplet's first-line NSCLC data
Sep 9, 2024 1:45pm
Sanofi, DualityBio, UCB—Fierce Pharma Asia
Aug 30, 2024 8:05am
J&J-Yuhan, Merck, biosecurity—Fierce Pharma Asia
Aug 23, 2024 10:05am
TROP2 ADCs, Merck-Daiichi, Eisai—Fierce Pharma Asia
Aug 9, 2024 8:25am
